Missing Script

Get updates

Evidence Explorer · MS-N297 · Nutrition and dietary patterns · Appraised November 10, 2026

A 150-person randomized trial reported modest improvements in weight and body-composition measures with 500 kcal/day of a balanced oral nutrition formula during gastrointestinal-cancer chemotherapy. It did not test tumor response or survival.

Evidence at a glance

  • Population: 150 people with gastrointestinal cancers receiving chemotherapy, assigned 75 per group.
  • Intervention: 500 kcal/day of a balanced oral nutrition formula for 12 weeks versus no study supplement.
  • Reported result: mean weight change was +1.27 ± 3.39 kg with supplementation versus +0.15 ± 0.42 kg in control.
  • Other findings: fat-mass, lean-mass-index, PG-SGA and selected biochemical measures favored supplementation.
  • Evidence label: supportive nutrition signal; no demonstrated cancer-control benefit.
  • Evidence label: Positive nutritional-status signal; cancer outcomes untested.

What was studied

The trial evaluated a defined calorie supplement rather than a generic commercial shake category. Changes in body composition and nutritional assessment are clinically relevant when intake is poor.

The abstract states that treatment delays may have been reduced, but the exact event counts and statistical estimate were not available in the abstract. That claim is therefore not quantified here.

What this evidence cannot establish

Cancer sites, stages and chemotherapy regimens were heterogeneous. The accessible report does not fully clarify allocation concealment, blinding, missing data or the clinical importance of each body-composition difference. Twelve weeks is too short for recurrence or survival conclusions.

Safety and practical context

A supplement adds calories, protein, carbohydrate, fat, fluid and micronutrients; the best formula depends on swallowing, diabetes, kidney or liver disease, diarrhea, pancreatic insufficiency and electrolyte status. Rapid feeding after severe undernutrition can cause refeeding problems. A product should supplement—not displace—tolerated meals unless a dietitian plans otherwise.

Questions for the care team

  • What calorie and protein gap is the formula meant to fill?
  • Does the formulation fit diabetes, kidney function, diarrhea, swallowing and pancreatic-enzyme needs?
  • Are we tracking weight, muscle, function and treatment tolerance—not albumin alone?

Sources and identifiers

Funding and conflicts: Funding, product provision and conflict details were not fully verified in this appraisal; readers should consult the full disclosure section before generalizing a formula-specific result.

Source access and dates: Primary reports, registries and official guidance available through the links above were checked November 10, 2026. Last literature search November 10, 2026. Fields unavailable from accessible full text are labeled not reported or not verified rather than assumed absent.

Educational evidence summary, not individualized medical advice. Restrictive diets or supplements should not replace established cancer treatment or adequate nutrition. Symptom, weight, biomarker, laboratory, imaging, pathology or animal findings do not by themselves establish tumor control, recurrence prevention or longer survival.